Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Biocytogen, Bionomics, C4X Discovery, Dr. Falk Pharma, Eisai, Eucure, Hitgen, HK Inno.N, Limmatech, Lupin, Sebela, Shionogi, Sumitomo, Sunovion, Syncromune, Takeda, Zedira.
With a 52% increase in patent filings and a 160% jump in research publications, the RNA technology field has exploded in the last 10 to 12 years, and the U.S. and mainland China are paving the way. Identifying seven emerging RNA innovators, Clarivate plc’s RNA Technology Companies to Watch is a new report that harnesses data and insights from both Clarivate and BioWorld.
Sumitovant Biopharma Ltd., a subsidiary of Sumitomo Pharma Co. Ltd., agreed to acquire Myovant Sciences Ltd. for $27 per share, up from its earlier offer of $22.75 per share. The deal is worth $1.7 billion on a fully diluted basis, with an equity value of about $2.59 billion.
Sinocelltech Group Ltd. has reported positive interim data for two COVID-19 vaccine candidates, SCTV-01C and SCTV-01E, from phase III trials in the United Arab Emirates.
Astellas Pharma Inc. has invested $50 million in Taysha Gene Therapies Inc. in exchange for 15% of the company and exclusive options to in-license Taysha’s lead gene therapy candidates, TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy.
Suzhou Zelgen Biopharmaceuticals Co. Ltd. reported a phase III trial testing the company’s deuterium-substituted sorafenib derivative donafenib in patients with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer met its primary endpoint following a preplanned interim analysis which found the drug significantly prolonged median progression-free survival vs. a placebo.
RSS
